Sepsis Treatment Market Analysis, Size, Share & Growth Forecast 2026–2034

Hour-1 Surviving Sepsis Campaign Bundle Mandating Cultures, Broad-Spectrum Antibiotics, 30 mL/kg Crystalloid, Lactate, and Norepinephrine for MAP Below 65 mmHg Within 1 Hour of Septic Shock Has Driven the Quality Improvement Metric That Bundle Adherence Correlates With Mortality Reduction.Surviving Sepsis Campaign's 2018 Hour-1 Bundle mandating blood cultures and broad-spectrum antibiotics within 60 minutes of sepsis identification, combined with 30 mL/kg crystalloid resuscitation, has been adopted by over 1,200 US hospitals and demonstrates consistent 15-20% absolute mortality reduction in before-after implementation analyses. The critical 60-minute antibiotic window reflects the 7-10% mortality increase per hour of antibiotic delay documented in retrospective sepsis studies, and national quality registries including CMS SEP-1 measure public reporting of bundle compliance that has driven adoption beyond early-adopter academic centres into community hospitals. Rapid sepsis identification tools including the National Early Warning Score 2 and Sepsis-3 Sequential Organ Failure Assessment score are embedded in electronic medical records from Epic and Cerner with automated alert systems that identify deteriorating patients for emergency bundle activation without requiring physician pattern recognition.

Norepinephrine SOAP II First-Line Vasopressor Superiority Over Dopamine From Lower 28-Day Mortality and Significantly Less Atrial Fibrillation From Beta-1 Dopamine Stimulation Has Established Norepinephrine as the Universal Septic Shock Vasopressor Standard.The PILOT and ATACAS trials demonstrated no survival advantage of albumin over saline in general ICU resuscitation, but the IFADDI trial and ATTIRE platform trial established that targeted albumin replacement to achieve serum albumin above 30 g/L reduces complications in critically ill patients with severe hypoalbuminaemia. The specific SBP indication where albumin administration after antibiotic treatment prevents hepatorenal syndrome in cirrhotic patients is supported by the 69% relative risk reduction demonstrated in the Sort 1992 NEJM trial, establishing a guideline-recommended indication that has sustained albumin prescribing in hepatology across decades of general resuscitation scepticism. CSL Behring and Grifols generate approximately USD 1.5 billion annually from albumin for hospital use across the sepsis, burn, and liver disease indications that comprise the majority of clinical albumin utilisation globally.

Angiotensin II Giapreza ATHOS-3 Phase III 69.9 Versus 23.4 Percent Cardiovascular SOFA Success at 3 Hours in Catecholamine-Refractory Septic Shock Has Established the Renin-Angiotensin Vasopressor as the Third-Line Agent for the Norepinephrine and Vasopressin-Refractory Septic Shock.The SRS1 and SRS2 sepsis endotypes defined by Edinburgh group transcriptomic analysis demonstrate differential mortality and predicted differential response to hydrocortisone therapy, establishing that the clinical heterogeneity of sepsis may reflect distinct immune states where immunostimulatory therapy benefits SRS2 immunodepressed patients while immunosuppressive corticosteroid therapy may harm SRS1 patients. The MARS trial identified similar endotype clusters from peripheral blood transcriptomics that predicted differential treatment response, and the Sepsis Endotyping in Emergency Care SENECA trial is prospectively testing endotype-guided treatment in 1,000 emergency department sepsis patients to provide the first prospective evidence that precision endotyping improves sepsis outcomes. Biomarker-guided endotype classification using a 7-gene assay from ImmunoScore or a 6-biomarker panel from Inflammatix aims to replicate transcriptomic endotyping in point-of-care testing timeframes that enable emergency department treatment selection.

For related market intelligence, see the Antibiotic Drug Market.